1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends

EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2024

  • October 2015
  • 74 pages
  • GlobalData
Report ID: 3389019

Summary

Table of Contents

Search Inside

EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2024

Summary

Acute myeloid leukemia (AML), also known as myelogenous leukemia, acute myelocytic leukemia, or acute nonlymphocytic leukemia, is a rare cancer that accounts for a disproportionally high number of cancer-related deaths. The disease is more common in the elderly, and is relatively more common in men than in women.

Acute promyelocytic leukemia (APL) and myelodysplastic syndromes (MDS)/therapy-related AML are two subtypes of AML that are especially unique in terms of disease etiology and prognosis, both of which will be discussed in detail in this report. Additionally, AML is associated with molecular gene mutations that are distinct from chromosomal structural abnormalities; of these, the best-studied is the FLT3 mutation (NCI, 2013). AML cases can also be stratified into three prognostic risk groups for treatment planning: favorable, intermediate, and adverse.

GlobalData epidemiologists estimate that the 7MM had 40,661 diagnosed incident cases of AML in 2014, nearly half of which occurred in the US. In the next 10 years, the 7MM will experience an increase in disease burden at a rate of 2.03% per year, which will be driven by population increase; this will result in 48,918 diagnosed incident cases of AML in 2024. For 2014, the number of diagnosed prevalent cases of AML was nearly identical to the number of diagnosed incident cases, at 44,079 cases, thereby underlining the lethality and poor long-term survival of the disease. The development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence.

Scope

The Acute Myeloid Leukemia (AML) EpiCast Report provides an overview of the risk factors and global trends of AML in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of the following segmentations in adults ages 20 years and older across the 7MM -
- Diagnosed incident cases of AML, segmented by sex and 10-year age groups
- Five-year diagnosed prevalent cases of AML, segmented by ages 20-59 years and ages 60 years and older
- Diagnosed incident and five-year diagnosed prevalent cases of APL and MDS/therapy-related AML, segmented by ages 20-59 years and ages 60 years and older
- Diagnosed incident cases of AML that have mutations in the FLT3 gene
- Diagnosed incident cases of AML classified into favorable, intermediate, and adverse risk groups
- The AML epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The AML EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global AML market.
- Quantify patient populations in the global AML market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AML therapeutics in each of the markets covered.
- Identify the percentage of AML cases by age, subtype, and risk group.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • March 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Global Acute Myeloid Leukemia (AML) Therapeutics - Pharmaceuticals

  • $ 4500
  • Industry report
  • March 2017
  • by Global Industry Analysts

This report analyzes the worldwide markets for Acute Myeloid Leukemia (AML) Therapeutics in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest ...

Opportunity in Leukemia Therapeutics in global market - 2017

  • $ 4500
  • Industry report
  • March 2017
  • by Feedback Business Consulting

This report provides insight into the current market scenario, structure and practices. In depth market scenario includes: - Current market size estimate - Revenues by players - Top 5 Companies - Market ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.